Epigenetic Clocks Predict Death Risk But Show Racial Disparities in US Adults
Study of 2,105 Americans reveals epigenetic age acceleration predicts mortality, but effectiveness varies significantly by race and ethnicity.
Summary
Researchers analyzed nine epigenetic clocks in 2,105 US adults aged 50+ over 17.5 years to predict mortality risk. The GrimAge clock most accurately predicted overall death risk, while different clocks showed varying effectiveness for cardiovascular and cancer deaths. Importantly, several epigenetic clocks that worked well in non-Hispanic White participants failed to predict mortality in Hispanic participants, revealing significant racial disparities in these aging biomarkers' clinical utility.
Detailed Summary
This groundbreaking study examined whether epigenetic clocks—molecular measures of biological aging—can accurately predict death risk across different populations. The research matters because these tools could revolutionize how we assess health span and target interventions, but only if they work equitably across all groups.
Researchers analyzed data from 2,105 Americans aged 50 and older from the National Health and Nutrition Examination Survey, following them for up to 20.7 years. They calculated epigenetic age acceleration (EAA) using nine different molecular clocks and tracked 998 deaths, including 272 from cardiovascular disease and 209 from cancer.
The GrimAge clock emerged as the strongest predictor of overall mortality, followed by Hannum, PhenoAge, Horvath, and Vidal-Bralo clocks. For cardiovascular deaths, GrimAge was most predictive, while Hannum, Horvath, and GrimAge clocks best predicted cancer mortality. These findings suggest different epigenetic signatures may capture distinct aging pathways.
However, the study revealed troubling disparities. While these clocks effectively predicted mortality in non-Hispanic White participants, the Horvath, Hannum, and GrimAge clocks failed to predict overall mortality in Hispanic participants. Similarly, the Hannum clock couldn't predict cancer deaths in Hispanic individuals. This suggests current epigenetic clocks may have been developed primarily on European ancestry populations.
These findings have significant implications for precision medicine and health equity. While epigenetic clocks show promise for personalized longevity interventions, their current limitations in diverse populations must be addressed before widespread clinical implementation.
Key Findings
- GrimAge clock most accurately predicted overall mortality risk over 17.5 years of follow-up
- Different epigenetic clocks showed varying effectiveness for cardiovascular versus cancer deaths
- Horvath, Hannum, and GrimAge clocks failed to predict mortality in Hispanic participants
- 998 deaths occurred among 2,105 participants, with 272 cardiovascular and 209 cancer deaths
- Epigenetic age acceleration varied significantly between different molecular clock algorithms
Methodology
Prospective cohort study using NHANES 1999-2002 data with up to 20.7 years follow-up. Epigenetic age acceleration calculated from residuals of nine different clocks regressed on chronological age, with Cox proportional hazards models adjusted for demographics and health factors.
Study Limitations
Study limited to participants aged 50+, potential survival bias, and epigenetic clocks may have been developed primarily on European ancestry populations. Sample sizes for some racial/ethnic subgroups were relatively small, limiting statistical power for stratified analyses.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.